Peregrine reports Phase II study data for bavituximab plus docetaxel in advanced breast cancer patients

Submit press release

Existing customer?
Log in

New customer?
Sign up

Latest Headlines
Motorola Mobility Notifies Certain Purchasers of Refurbished Motorola...
DNR Commemorates Conservation Officer's Death, Honors His...
Campaign tackles domestic violence ahead of Six Nations...
Justice Department Announces Luke J...
City of Lansing's River Trail closed at the M-43/Saginaw Street...
Michigan Liquor Control Commission Offers Tips on How to Host a...

M2 Archive: Preview

You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.

Peregrine reports Phase II study data for bavituximab plus docetaxel in advanced breast cancer patients
21 October 2009 - US-based biopharmaceutical company Peregrine Pharmaceuticals Inc (NASDAQ: PPHMD) reported today encouraging results from the Phase II study evaluating bavituximab in combination with docetaxel in patients with advanced breast cancer.
Preliminary data at the end of the six...

If you want to view the full text, you must first purchase archive credits.
Return to Archives
New Search